司库奇尤单抗治疗脊柱关节炎伴跟腱附着点炎的疗效与安全性:一项3b期试验结果
ACHILLES研究纳入204例活动性银屑病关节炎或中轴型脊柱关节炎伴跟腱附着点炎患者,随机接受司库奇尤单抗150/300 mg或安慰剂至第24周。第24周司库奇尤单抗组跟腱附着点炎消退比例高于安慰剂组但未达统计学显著(42.2% vs 31.4%,P=0.136),患者报告结局有临床意义改善,但中心判读MRI显示相当比例患者无炎症征象。
要点
- 第24周跟腱附着点炎消退比例司库奇尤单抗组42.2% vs 安慰剂组31.4%,未达统计学显著(P=0.136)。
- 基于Leeds附着点炎指数的消退比例司库奇尤单抗组33.3% vs 安慰剂组23.5%,OR=1.65(95%CI 0.85, 3.25)。
- 中心判读MRI显示56%存在骨髓水肿和/或肌腱炎,临床诊断与影像评估存在差异。
核心结论
- 尽管ACHILLES未达到主要终点,研究报告了患者相关结局的临床意义改善。
- 相当比例患者临床诊断为跟腱附着点炎但中心判读MRI无炎症征象,提示临床与影像评估附着点炎的差异需进一步研究。
研究设计与样本
- ACHILLES为3b期试验,纳入204例≥18岁活动性银屑病关节炎或中轴型脊柱关节炎伴足跟附着点炎患者。
- 患者按1:1随机接受司库奇尤单抗150/300 mg或安慰剂至第24周,此后安慰剂组患者转换为司库奇尤单抗。
- 试验注册号:clinicaltrials.gov,NCT02771210。
主要发现
- 第24周司库奇尤单抗组受影响足跟腱附着点炎消退比例42.2% vs 安慰剂组31.4%(OR=1.63;95%CI 0.87, 3.08;P=0.136),未达统计学显著。
- 第24周基于Leeds附着点炎指数的附着点炎消退比例司库奇尤单抗组33.3% vs 安慰剂组23.5%(OR=1.65;95%CI 0.85, 3.25)。
- 第24周足跟疼痛较基线平均变化司库奇尤单抗组-2.8(3.0) vs 安慰剂组-1.9(2.7)。
- 司库奇尤单抗在足跟附着点病变活动度和疾病活动度总体评估方面观察到更大改善。
- 筛查时局部判读MRI确认所有患者存在足跟附着点炎;中心判读显示56%存在骨髓水肿和/或肌腱炎,事后分析按HEMRIS评分76%有附着点炎症征象、86%有附着点炎症和/或结构改变。
关键数值与推荐
- 主要终点为第24周受影响足跟腱附着点炎消退比例,司库奇尤单抗组42.2% vs 安慰剂组31.4%,P=0.136,未达统计学显著。
- 基于Leeds附着点炎指数的消退比例司库奇尤单抗组33.3% vs 安慰剂组23.5%,OR=1.65(95%CI 0.85, 3.25)。
临床怎么用
- 原文未据此给出推荐。
局限性
- ACHILLES未达到主要终点。
- 临床诊断与影像评估附着点炎存在差异,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles' tendon enthesitis in spondyloarthritis (SpA) patients. METHODS: Patients ≥18 years (n = 204) with active PsA or axial SpA and heel enthesitis were randomized 1:1 to secukinumab 150/300 mg or placebo up to week 24, and thereafter placebo patients were switched to secukinumab. RESULTS: At week 24, a higher, yet statistically non-significant (P = 0.136), proportion of patients in secukinumab vs placebo reported resolution of Achilles tendon enthesitis in affected foot (42.2% vs 31.4%; odds ratio [OR] = 1.63; 95% CI: 0.87, 3.08). Proportion of patients reporting resolution of enthesitis based on Leeds Enthesitis Index was higher with secukinumab vs placebo (33.3% vs 23.5%; OR = 1.65; 95% CI: 0.85, 3.25) at week 24. Mean change from baseline in heel pain at week 24 was higher in secukinumab patients vs placebo (-2.8 [3.0] vs -1.9 [2.7]). Greater improvements with secukinumab were observed in heel enthesopathy activity and global assessment of disease activity. Imaging evaluation by local reading confirmed heel enthesitis on MRI at screening for all patients. Based on central reading, 56% presented with bone marrow oedema and/or tendinitis; according to Heel Enthesitis MRI Scoring System (HEMRIS) post hoc analysis, 76% had signs of entheseal inflammation while 86% had entheseal inflammation and/or structural changes. CONCLUSION: A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging assessments of enthesitis requires further investigation. Although ACHILLES did not meet the primary end point, the study reported clinically meaningful improvements in patient-related outcomes. TRIAL REGISTRATION: clinicaltrials.gov, NCT02771210.
引用
- Behrens F, Sewerin P, de Miguel E, et al. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. Rheumatology (Oxford). 2022. PMID: 34730795. doi:10.1093/rheumatology/keab784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。